MedTrace Logo

The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders

NCT04727476 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 413

Last updated 2021-08-11

No results posted yet for this study

Summary

Aiming at improving clinical practice regarding the use of lisdexamfetamine for the treatment of ADHD in children, the investigators want to retrospectively map the clinical use of lisdexamfetamine at a specialised outpatient clinic located at Aarhus University Hospital, Denmark treating children aged 7-13 with Attention Deficit Disorders in the period from 2013 to 2019. The investigators will describe the changes in prescription practice in the period, reported side effects and reasons for selecting and discontinuing treatment with lisdexamfetamine.

Conditions

  • Attention Deficit Disorder
  • Attention Deficit Hyperactivity Disorder
  • Hyperkinetic Disorder

Interventions

DRUG

Lisdexamfetamine

Prescription of lisdexamfetamine sometime during til period from 1 April 2013 to 5 November 2019.

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • Aarhus University Hospital

    lead OTHER

Principal Investigators

  • Nanna Roed Soendergaard, MD · Department of Child and Adolescent Psychiatry, Aarhus University Hospital, Denmark

Eligibility

Min Age
7 Years
Max Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-19
Primary Completion
2021-08-10
Completion
2022-05-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04727476 on ClinicalTrials.gov